The Application of B-type Natriuretic Peptide Detection in Hospital Level among Inpatients with Heart Failure in China
China Oxford Centre for International Health Research,State Key Laboratory of Cardiovascular Disease,NHC Key Laboratory of Clinical Research for Cardiovascular Medications,National Clinical Research Center of Cardiovascular Diseases,National Center for Cardiovascular Diseases,Fuwai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China
*Corresponding author:TIAN Lei,Associate professor;E-mail:tianlei0807@163.com
CHAI Lin,BAI Xueke,SU Meng, et al. The Application of B-type Natriuretic Peptide Detection in Hospital Level among Inpatients with Heart Failure in China [J]. Chinese General Practice, 2020, 23(5): 553-558. DOI: 10.12114/j.issn.1007-9572.2019.00.748.
柴琳,白雪珂,苏萌等. 我国心力衰竭住院诊疗中B型利钠肽检测在医院水平的应用分析研究[J]. 中国全科医学, 2020, 23(5): 553-558. DOI: 10.12114/j.issn.1007-9572.2019.00.748.
[1]SAKATA Y,SHIMOKAWA H.Epidemiology of heart failure in Asia[J].Circ J,2013,77(9):2209-2217.DOI:10.1253/circj.cj-13-0971.
[2]ZHANG Y H,ZHANG J,BUTLER J,et al.Contemporary epidemiology,management,and outcomes of patients hospitalized for heart failure in China:results from the China heart failure(China-HF) registry[J].J Card Fail,2017,23(12):868-875.DOI:10.1016/j.cardfail.2017.09.014.
[3]胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.DOI:10.3969/j.issn.1000-3614.2019.03.001.
HU S S,GAO R L,LIU L S,et al.Summary of the 2018 report on cardiovascular diseases in China[J].Chinese Circulation Journal,2019,34(3):209-220.DOI:10.3969/j.issn.1000-3614.2019.03.001.
[4]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.DOI:10.3760/cma.j.issn.0253-3758.2018.10.004.http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhxxgb201810004.
[5]COOK C,COLE G,ASARIA P,et al.The annual global economic burden of heart failure[J].Int J Cardiol,2014,171(3):368-376.DOI:10.1016/j.ijcard.2013.12.028.
[6]CHOW S L,MAISEL A S,ANAND I,et al.Role of biomarkers for the prevention,assessment,and management of heart failure:a scientific statement from the American Heart Association[J].Circulation,2017,135(22):e1054-1091.DOI:10.1161/CIR.0000000000000490.
[7]TANG W H,FRANCIS G S,MORROW D A,et al.National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines:clinical utilization of cardiac biomarker testing in heart failure[J].Circulation,2007,116(5):e99-109.DOI:10.1161/CIRCULATIONAHA.107.185267.
[8]张玉涛.心力衰竭患者超敏肌钙蛋白T、超敏C反应蛋白、生长分化因子—15及氨基末端脑钠肽的临床价值[D].济南:山东大学,2018.
[9]杨跃进.B-型利钠肽在心力衰竭诊断和治疗中的应用[J].中国循环杂志,2004,19(2):83-85.http://www.cnki.com.cn/Article/CJFDTotal-ZGXH200402000.htm.
[10]张国华,胡韵,史晓敏,等.B型钠尿肽的生物学特性及其在心脏病学中的临床应用进展[J].中华检验医学杂志,2004,27(4):262-265.DOI:10.3760/j:issn:1009-9158.2004.04.020.http://www.cnki.com.cn/Article/CJFDTotal-ZHYJ200404022.htm.
[11]MAISE A,MUELLER C,PEACOCK W F,et al.2008中西方BNP专家共识[J].胡大一,刘梅颜,吴寸草,等,译.中国医药导刊,2009,11(10):1628-1637.
[12]YANCY C W,JESSUP M,BOZKURT B,et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America[J].Circulation,2017,136(6):e137-161.DOI:10.1161/CIR.0000000000000509.
[13]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.DOI:10.3760/cma.j.issn.0253-3758.2014.02.004.http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhxxgb201402004.
[14]PONIKOWSKI P,VOORS A A,ANKER S D,et al.2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure:the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J].Eur Heart J,2016,37(27):2129-2200.DOI:10.1093/eurheartj/ehw128.
[15]YU Y,ZHANG H Z,LI X,et al.The China Patient-centered Evaluative Assessment of Cardiac Events(China PEACE) retrospective heart failure study design[J].BMJ Open,2018,8(5):e020918.DOI:10.1136/bmjopen-2017-020918.
[16]Writing Committee Members,YANCY C W,JESSUP M,et al.2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure:an update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America[J].Circulation,2016,134(13):e282-293.DOI:10.1161/CIR.0000000000000435.
[17]JANUZZI J L,TROUGHTON R.Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management[J].Circulation,2013,127(4):500-507;discussion 508.DOI:10.1161/CIRCULATIONAHA.112.120485.
[18]徐国宾,史晓敏.B型钠尿肽及N末端B型钠尿肽原在临床应用中值得关注的几个问题[J].中华检验医学杂志,2006,29(1):9-11.DOI:10.3760/j:issn:1009-9158.2006.01.004.
XU G B,SHI X M.Issues that challenge our attention about B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in clinical use[J].Chinese Journal of Laboratory Medicine,2006,29(1):9-11.DOI:10.3760/j:issn:1009-9158.2006.01.004.